Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-low Breast Cancer”

181 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 181 results

Not applicableStudy completedNCT06386263
What this trial is testing

HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada

Who this might be right for
Unresectable Breast CancerMetastatic Breast CancerHER2-low Expressing Breast Cancer+1 more
AstraZeneca 22
Large-scale testing (Phase 3)Not Yet RecruitingNCT06561607
What this trial is testing

A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 542
Testing effectiveness (Phase 2)Looking for participantsNCT06207734
What this trial is testing

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Who this might be right for
Breast Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 120
Large-scale testing (Phase 3)Active Not RecruitingNCT05840211
What this trial is testing

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Who this might be right for
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast Cancer
Gilead Sciences 654
Testing effectiveness (Phase 2)Active Not RecruitingNCT05165225
What this trial is testing

Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Who this might be right for
Breast CancerHER2-low-expressing Breast CancerHormone Receptor-positive Breast Cancer+1 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 48
Testing effectiveness (Phase 2)Looking for participantsNCT06298084
What this trial is testing

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd

Who this might be right for
Breast Cancer MetastaticHER2-positive Metastatic Breast CancerHER2 Low Breast Carcinoma+1 more
Gustave Roussy, Cancer Campus, Grand Paris 152
Not applicableLooking for participantsNCT05831878
What this trial is testing

RC48-ADC in HER2-low Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
RenJi Hospital 36
Testing effectiveness (Phase 2)Looking for participantsNCT05911958
What this trial is testing

SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

Who this might be right for
HER2 Low Breast Carcinoma
Henan Cancer Hospital 66
Not applicableLooking for participantsNCT06877416
What this trial is testing

Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer

Who this might be right for
Antibody-drug ConjugatesHER2-low Breast CancerBreast Neoplasms
Sun Yat-sen University 700
Testing effectiveness (Phase 2)Looking for participantsNCT06797635
What this trial is testing

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Who this might be right for
Breast NeoplasmsBreast Cancer
Merck Sharp & Dohme LLC 372
Early research (Phase 1)Looking for participantsNCT05461768
What this trial is testing

BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors

Who this might be right for
Breast CancerLocally Advanced or Metastatic Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd. 26
Testing effectiveness (Phase 2)Looking for participantsNCT06411457
What this trial is testing

SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 20
Testing effectiveness (Phase 2)WithdrawnNCT06105008
What this trial is testing

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
RemeGen Co., Ltd.
Testing effectiveness (Phase 2)Study completedNCT00944047
What this trial is testing

Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression

Who this might be right for
Breast Cancer
University of Kansas Medical Center 32
Not applicableNot Yet RecruitingNCT06492447
What this trial is testing

Correlation Study of Serum HER 2 Against HER 2-ADC Drug Efficacy in HER 2 Low-expressing Breast Cancer

Who this might be right for
HER 2 Low-expressing Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 50
Early research (Phase 1)WithdrawnNCT04602117
What this trial is testing

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Who this might be right for
HER2-positive Breast CancerHER2 LowSYD-985+24 more
QuantumLeap Healthcare Collaborative
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06975462
What this trial is testing

A Phase II Study of SHR-A1811 Combined With Radiotherapy in HER2-positive and HER2-low Breast Cancer Brain Metastases

Who this might be right for
Breast Cancer Metastatic
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 30
Testing effectiveness (Phase 2)Looking for participantsNCT05795101
What this trial is testing

TRUDI: TDXD+Durva in HER2+/Low IBC

Who this might be right for
Invasive Breast CancerInflammatory Breast Cancer Stage IIIHER2-positive Breast Cancer+2 more
Filipa Lynce, MD 63
Large-scale testing (Phase 3)Study completedNCT01275677
What this trial is testing

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Who this might be right for
HER2/Neu PositiveProgesterone Receptor PositiveRecurrent Breast Carcinoma+6 more
National Cancer Institute (NCI) 3,270
Early research (Phase 1)Ended earlyNCT02598427
What this trial is testing

Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer

Who this might be right for
HER2 Positive Untreated Metastatic Breast CancerAsymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer
Kimberly Blackwell 1
Load More Results